BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful ...

Gilead is to buy Nimbus Therapeutics' liver drug subsidiary in a deal worth up to $1.2 billion as it aims to build on the success of its hepatitis C franchise. The Nimbus Apollo deal is small ...

This week saw a series of big-ticket funding rounds for biotech companies, with Apollo Therapeutics and Nimbus Therapeutics both pulling in upwards of $200 million, in a positive sign for private ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

In this Expert View column, Abbas Kazimi, chief business officer of Nimbus Therapeutics, discusses the advantages of a ...

Nimbus Therapeutics has used these approaches and established a successful track record of delivering clinical candidates for targets such as Tyk2 and HPK1 that have proven difficult for other drug ...

Company to present pipeline update at 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT -- Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a ...

Company to present pipeline update at 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT -- BOSTON, January 09, 2025--(BUSINESS WIRE)--Nimbus Therapeutics ...